Loading
Life sciences · Journal article
Phytotherapy Research · August 31, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic review that surveys proposed roles of nutraceutical compounds (polyphenols, omega-3 fatty acids, anthocyanins, and others) as adjuncts to conventional heart failure and atrial fibrillation therapy, grounded in proposed biological pathways rather than clinical trial evidence. The authors acknowledge that nutraceuticals are not substitutes for established therapies and call for large-scale trials, but do not synthesize or quantify existing clinical evidence to support routine integration into cardiovascular care.
Narrative review. Patients with heart failure and atrial fibrillation, often coexisting..
Polyphenols from Olea europaea, Hibiscus sabdariffa, Camellia sinensis, and Vitis vinifera exhibit proposed antioxidant, anti-inflammatory, and vasoprotective effects in theoretical models. Omega-3 fatty acids and astaxanthin proposed to contribute to inflammation control and redox balance. Orthosiphon stamineus and Taraxacum officinale noted to show mild diuretic activity.
No assessment of bioavailability, dosage ranges, or safety profiles for any compound.
This review does not present sufficient clinical evidence to recommend changes to practice. Clinicians should view proposed nutraceutical adjuncts as speculative pending rigorous trial data; the article itself emphasizes that nutraceuticals remain unproven as complements to guideline-directed therapies.
This is a narrative review article that raises mechanistic questions about nutraceuticals in cardiovascular disease but does not present original experimental or clinical data, trial results, or systematic evidence synthesis to support definitive claims.
As stated by the source record.
This review does not present sufficient clinical evidence to recommend changes to practice. Clinicians should view proposed nutraceutical adjuncts as speculative pending rigorous trial data; the article itself emphasizes that nutraceuticals remain unproven as complements to guideline-directed therapies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Heart failure (HF) and atrial fibrillation (AF) are among the most prevalent cardiovascular diseases, often coexisting and sharing common pathophysiological pathways such as systemic inflammation, oxidative stress, mitochondrial dysfunction, and endothelial impairment. Despite substantial progress in pharmacological treatment, including renin-angiotensin-aldosterone system (RAAS) inhibitors, beta-blockers, sodium-glucose cotransporter 2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists (MRAs), diuretics, and antiarrhythmic drugs, many patients continue to experience residual symptoms and drug-related adverse effects. Nutraceuticals have emerged as potential adjuncts to conventional therapy due to their ability to modulate key biological processes involved in HF and AF. Polyphenols from Olea europaea, Hibiscus sabdariffa, Camellia sinensis, and Vitis vinifera (resveratrol) exhibit antioxidant, anti-inflammatory, and vasoprotective effects. Omega-3 fatty acids and astaxanthin contribute to inflammation control and redox balance, while Orthosiphon stamineus and Taraxacum officinale show mild diuretic activity. Moreover, anthocyanins, ursolic acid, and Rhodiola crenulata may exert antifibrotic and antiarrhythmic properties. This review provides a mechanistic comparison between pharmacological agents and nutraceuticals with overlapping mechanisms of action, highlighting their potential role in integrative cardiovascular care. While nutraceuticals are not substitutes for established therapies, emerging evidence supports their complementary use in improving treatment response, reducing side effects, and enhancing patient outcomes. Future research should focus on large-scale trials, improved bioavailability, standardized formulations, and the development of personalized therapeutic strategies. Challenges related to dosage consistency, clinical validation, and regulatory oversight are also addressed to guide innovation in integrative cardiology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.